Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bone morphogenetic protein 7 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | 0.03 mg/ml BMP-7, single intraarticular knee injection |
| Arm 2 | ACTIVE_COMPARATOR | 0.1 mg/ml BMP-7, single intraarticular knee injection |
| Arm 3 | ACTIVE_COMPARATOR | 0.3 mg/ml BMP-7, single intraarticular knee injection |
| Arm 4 | PLACEBO_COMPARATOR | 1 ml placebo, single intraarticular knee injection (control) |
| Cohort 1 | EXPERIMENTAL | 0.03 mg/ml BMP-7 or placebo via intraarticular knee injection |
| Cohort 2 | EXPERIMENTAL | 0.1 mg/ml BMP-7 or placebo via intraarticular knee injection |
| Cohort 3 | EXPERIMENTAL | 0.3 mg/ml BMP-7 or placebo via intraarticular knee injection |
| Name | Type | Description |
|---|---|---|
| Bone morphogenetic protein 7 | DRUG | Comparison of different doses of the drug via single intraarticular knee injection |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Ambulatory with a diagnosis of OA of the knee with symptoms for at least 6 months and pain on the majority of days in the last 30 days. Symptoms must include knee joint pain. * A male or female adult age \>40 years * female subjects of childbearing potential must have a negati...
Bone morphogenetic protein 7 is an investigational small molecule being developed for osteoarthritis of the knee. It is administered intraarticularly and is currently in clinical development, with completed Phase 1 and Phase 2 trials. It is not approved by the FDA and remains investigational.
Bone morphogenetic protein 7 is being developed by Stryker Corporation, which trades under the ticker SYK. The company has conducted clinical trials for this drug in the United States for osteoarthritis of the knee.
Bone morphogenetic protein 7 is in Phase 2 clinical development. It has completed a Phase 2 dose-finding study and a Phase 1 safety study, both in patients with osteoarthritis of the knee. The drug is investigational and not yet approved.
Bone morphogenetic protein 7 has completed two clinical trials: NCT01111045, a Phase 2 dose-finding study with 355 participants, and NCT01133613, a Phase 1 single-dose escalation safety study with 51 participants. Both trials were conducted in the United States in patients with knee osteoarthritis.
Bone morphogenetic protein 7 is a small molecule that targets bone morphogenetic protein 7, a protein involved in bone and cartilage formation. In osteoarthritis of the knee, it is being studied for its potential to modify the disease process, though its exact mechanism in this context is not fully detailed.